الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 138 |  |  |
| | | from | 138 | | |
Abstract
The thesis contains three chapters, concerned with synthesis and characterization of new transition metal complexes of 5,6-diamino-4-hydroxy-2-mercaptopyrimidine (Hdahmp) and and their use as anticancer agents.
Part I: Introduction
This chapter concerned with literature survey on the chemistry of Pyrimidines, Chemistry of Pyrimidine and Substituted Pyrimidines, Chemistry of Uracil and Thiouracils, Complexes of 2-Mercaptopyrimidines, Transition Metal Complexes as Anticancer Drugs, included survey on Cancer treatment and Anticancer Activity of N,O- N,S and N,O,S-Donors complexes.
Part II: Experimental
This chapter is concerned with the synthesis of new complexes of 5,6-diamino-4-hydroxy-2-mercaptopyrimidine (Hdahmp), [Zn(dahmp)2Cl2], [Zn(dahmp)(bpy)]Cl, [Zn(Hdahmp)2]SO4, [Pd(Hdahmp)(dahmp)]Cl, [Pt(dahmp-H)]n, [M(bpy)(dahmp)]Cl, [M(bpy)(Hdahmp]Cl2 (M(II) = Pd, Pt), [Ru(dahmp)2(PPh3)2], [Rh(dahmp)2(H2O)2]Cl, [Ag2(Hdahmp)2], cis-[MoO2(dahmp)2], cis-[WO2(dahmp)2], cis-[MoO2(dahmp.3HCl)2], cis-[MoO2(Hdahmp)(DMF)Cl]Cl and trans-[UO2(dahmp)2].
The methods and measurements of the anticancer activity against the serous ovarian cancer ascites (OV90) and human ovarian cancer (OVCAR-8) cell lines cell lines are also reported. The chemical measurements, elemental analysis and molar conductivity are also reported.
Part III: Results and Discussion
This part is concerned with the characterization of the isolated complexes by a variety of physical and chemical techniques including IR, (1H, 31P, 13C) NMR, electronic and mass spectroscopy, molar conductivity and thermal measurements.
Applications
Examination of 5,6-diamino-4-hydroxy-2mercaptopyrimidine (Hdahmp) and its complexes against the human serous ovarian cancer ascites (OV90) and ovarian cancer (OVCAR-8) cells cell line.
The in vitro anticancer activity of the free Hdahmp and its complexes, [Zn(Hdahmp)2Cl2], [Zn(bpy)(dahmp)]Cl, cis-[MoO2(dahmp)2], [Pd(dahmp)(Hdahmp)]Cl, [Pd(bpy)(dahmp)]Cl and [M(Hdahmp)(bpy)]Cl2 (M(II) = Pd, Pt) and [Ag2(dahmp)2], were tested against the serous ovarian cancer ascites (OV-90) and human ovarian cancer (OVCAR-8) cell lines, in comparison to cis-platin as a reference. The complexes, [Pd(dahmp)(Hdahmp)]Cl, [Pd(dahmp)(bpy)]Cl, [Pd(Hdahmp)(bpy)]Cl2, [Pt(Hdahmp)(bpy)]Cl2 and [Ag2(dahmp)2] exhibit high growth inhibitor activity with mean IC50 values of 12.53, 25.60, 8.41, 4.02 and 5.22 μM (OV-90) and 11.31, 20.66, 6.43, 3.08 and 3.04 μM (OVACAR-8), respectively; the IC50 values of cis-platin being 31.06 and 30.86 μM. The activity of [Pt(bpy)(Hdahmp)]Cl2 complex may be due to its square-planar geometry. An important property of Pt(II) complexes is the fact that Pt-ligand bonds (Pt-S, Pt-N), which have the thermodynamic strength of a typical coordination bond, are much weaker than C-C, C-N or C-O covalent bonds; the data obtained from TGA analysis, confirming this feature. However, the ligand exchange behavior in Pt complexes is quite slow, which gives them high kinetic stability. Thus, the ligand exchange reactions take place in minutes to days, rather than microseconds to seconds as in case of Pd(II) complexes [52]. The activity of the [Ag2(dahmp)2] complex is as expected, since Ag(I) complexes have been reported as active anti-cancer agents and wound healing stimulators . The activity of mixed Hdahmp - bpy complexes, [M(Hdahmp)(bpy)]Cl2 (M(II) = Pd, Pt) and [Pd(dahmp)(bpy)]Cl, are attributed to their square-planar geometry as well as the nature and (cis-bpy donation).